Exploring the combined therapeutic efficacy of bexarotene and icariin in type 2 diabetic rats
Journal of Pharmacy and Pharmacology · 04.11.2024 · 76 (11) · 1474-1481
DOI: 10.1093/jpp/rgae100 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, online erschienen am 03.08.2024. Verfasst von Burak Dik und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Selcuk University, Konya, 42130, Türkiye. Hauptthemen laut MEDLINE: Flavonoids, Bexarotene, Hypoglycemic Agents, Diabetes Mellitus, Experimental. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 64 Literaturangaben. Gefördert von: Selcuk University Scientific Research Projects.
Abstract (Originalsprache)
Objectives
The aim of this study was to determine the single and combined antidiabetic activity and side effects of the retinoid X receptor agonist bexarotene and the thioredoxin-interacting protein inhibitor and peroxisome proliferator-activated receptor γ and AMP-activated protein kinase activator icariin.
Methods
The rats were grouped as healthy (control), diabetes, diabetes + bexarotene (20 mg/kg), diabetes + icariin (60 mg/kg), diabetes + bexarotene (10 mg/kg) + icariin (30 mg/kg) low-dose combination and diabetes + bexarotene (20 mg/kg) + icariin (60 mg/kg) high-dose combination groups. Key findings Icariin treatment led to a significant reduction in glucose levels compared with the diabetes control group, a remarkable outcome observed 45 days after the initial application. HbA1c levels of the icariin and low-dose combination treatment groups were significantly lower than in the diabetes group. Notably, icariin treatment also significantly elevated HOMA-β levels, which is indicative of improved β-cell function. Icariin significantly decreased glucose levels at 30 and 120 min in the oral glucose tolerance test. Moreover, it ameliorated hepatocyte degeneration, hepatic cord dissociation, congestion, mononuclear cell infiltration in the liver, and degeneration in the pancreas.
Conclusions
Icariin treatment exhibited robust antidiabetic effects with fewer side effects than other treatment options in this study. In future studies, long-term and varying doses of icariin will contribute to the development of novel antidiabetic drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, Selcuk University, Konya, 42130, Türkiye.
- Department of Pathology, Selcuk University, Konya, 42130, Türkiye.
ORCID-Profile: Burak Dik, Tugba Melike Parlak, Oznur Tufan
Förderung
- Selcuk University Scientific Research Projects
Zitieren
APA
Dik, B., Parlak, T. M., Ates, M. B., & Tufan, O. (2024). Exploring the combined therapeutic efficacy of bexarotene and icariin in type 2 diabetic rats. Journal of Pharmacy and Pharmacology, 76(11), 1474-1481. https://doi.org/10.1093/jpp/rgae100
Vancouver
Dik B, Parlak TM, Ates MB, Tufan O. Exploring the combined therapeutic efficacy of bexarotene and icariin in type 2 diabetic rats. Journal of Pharmacy and Pharmacology. 2024;76(11):1474-1481. doi:10.1093/jpp/rgae100
BibTeX
@article{Dik2024,
author = {Dik, Burak and Parlak, Tugba Melike and Ates, Mehmet Burak and Tufan, Oznur},
title = {Exploring the combined therapeutic efficacy of bexarotene and icariin in type 2 diabetic rats},
journal = {Journal of Pharmacy and Pharmacology},
year = {2024},
volume = {76},
number = {11},
pages = {1474--1481},
doi = {10.1093/jpp/rgae100}
}
EUVIMED